PROTAGONIST THERAPEUTICS INC (PTGX) Fundamental Analysis & Valuation
NASDAQ:PTGX • US74366E1029
95.42 USD
-1.06 (-1.1%)
At close: Mar 12, 2026
95.42 USD
0 (0%)
After Hours: 3/12/2026, 8:06:01 PM
This PTGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 5 out of 10 to PTGX. PTGX was compared to 519 industry peers in the Biotechnology industry. While PTGX has a great health rating, there are worries on its profitability. PTGX has a correct valuation and a medium growth rate.
1. PTGX Profitability Analysis
1.1 Basic Checks
- PTGX had negative earnings in the past year.
- PTGX had a positive operating cash flow in the past year.
- PTGX had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: PTGX reported negative operating cash flow in multiple years.
1.2 Ratios
- PTGX has a Return On Assets of -19.48%. This is in the better half of the industry: PTGX outperforms 76.30% of its industry peers.
- The Return On Equity of PTGX (-21.17%) is better than 81.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.48% | ||
| ROE | -21.17% | ||
| ROIC | N/A |
ROA(3y)-1.53%
ROA(5y)-18.42%
ROE(3y)-1.29%
ROE(5y)-20.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for PTGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. PTGX Health Analysis
2.1 Basic Checks
- PTGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- PTGX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, PTGX has more shares outstanding
- PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 68.33 indicates that PTGX is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 68.33, PTGX belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
- There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 68.33 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
- A Current Ratio of 12.71 indicates that PTGX has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 12.71, PTGX belongs to the best of the industry, outperforming 87.28% of the companies in the same industry.
- A Quick Ratio of 12.71 indicates that PTGX has no problem at all paying its short term obligations.
- PTGX's Quick ratio of 12.71 is amongst the best of the industry. PTGX outperforms 87.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.71 | ||
| Quick Ratio | 12.71 |
3. PTGX Growth Analysis
3.1 Past
- The earnings per share for PTGX have decreased strongly by -148.81% in the last year.
- Looking at the last year, PTGX shows a very negative growth in Revenue. The Revenue has decreased by -89.41% in the last year.
- The Revenue has been growing by 9.96% on average over the past years. This is quite good.
EPS 1Y (TTM)-148.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-134.85%
Revenue 1Y (TTM)-89.41%
Revenue growth 3Y20.07%
Revenue growth 5Y9.96%
Sales Q2Q%-95.64%
3.2 Future
- PTGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.02% yearly.
- PTGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.29% yearly.
EPS Next Y192.01%
EPS Next 2Y29.39%
EPS Next 3Y34.01%
EPS Next 5Y30.02%
Revenue Next Year619.9%
Revenue Next 2Y88.3%
Revenue Next 3Y82.33%
Revenue Next 5Y63.29%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. PTGX Valuation Analysis
4.1 Price/Earnings Ratio
- PTGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 50.59, the valuation of PTGX can be described as expensive.
- Based on the Price/Forward Earnings ratio, PTGX is valued cheaply inside the industry as 90.56% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, PTGX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 50.59 |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 91.52% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 108.57 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- PTGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as PTGX's earnings are expected to grow with 34.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.39%
EPS Next 3Y34.01%
5. PTGX Dividend Analysis
5.1 Amount
- PTGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PTGX Fundamentals: All Metrics, Ratios and Statistics
95.42
-1.06 (-1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)05-04 2026-05-04/amc
Inst Owners111.7%
Inst Owner Change-0.45%
Ins Owners1.12%
Ins Owner Change2.21%
Market Cap6.09B
Revenue(TTM)46.02M
Net Income(TTM)-130.15M
Analysts84.21
Price Target102.55 (7.47%)
Short Float %13.91%
Short Ratio11.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.58%
Min EPS beat(2)-28.03%
Max EPS beat(2)4.88%
EPS beat(4)3
Avg EPS beat(4)0.76%
Min EPS beat(4)-28.03%
Max EPS beat(4)19.4%
EPS beat(8)7
Avg EPS beat(8)88.33%
EPS beat(12)10
Avg EPS beat(12)177.55%
EPS beat(16)13
Avg EPS beat(16)137.28%
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-18.32%
Max Revenue beat(2)27.04%
Revenue beat(4)1
Avg Revenue beat(4)-5.05%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)27.04%
Revenue beat(8)4
Avg Revenue beat(8)49.08%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10.83%
EPS NQ rev (1m)7.96%
EPS NQ rev (3m)4%
EPS NY rev (1m)405.54%
EPS NY rev (3m)389.08%
Revenue NQ rev (1m)5.08%
Revenue NQ rev (3m)-12.44%
Revenue NY rev (1m)28.07%
Revenue NY rev (3m)42.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 50.59 | ||
| P/S | 132.32 | ||
| P/FCF | 108.57 | ||
| P/OCF | 105.58 | ||
| P/B | 9.91 | ||
| P/tB | 9.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.05
EYN/A
EPS(NY)1.89
Fwd EY1.98%
FCF(TTM)0.88
FCFY0.92%
OCF(TTM)0.9
OCFY0.95%
SpS0.72
BVpS9.63
TBVpS9.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.48% | ||
| ROE | -21.17% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 121.87% |
ROA(3y)-1.53%
ROA(5y)-18.42%
ROE(3y)-1.29%
ROE(5y)-20.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 124.22% | ||
| Cap/Sales | 3.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 12.71 | ||
| Quick Ratio | 12.71 | ||
| Altman-Z | 68.33 |
F-Score4
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)63.14%
Cap/Depr(5y)80.58%
Cap/Sales(3y)1.59%
Cap/Sales(5y)2.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-148.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-134.85%
EPS Next Y192.01%
EPS Next 2Y29.39%
EPS Next 3Y34.01%
EPS Next 5Y30.02%
Revenue 1Y (TTM)-89.41%
Revenue growth 3Y20.07%
Revenue growth 5Y9.96%
Sales Q2Q%-95.64%
Revenue Next Year619.9%
Revenue Next 2Y88.3%
Revenue Next 3Y82.33%
Revenue Next 5Y63.29%
EBIT growth 1Y-162.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year259.07%
EBIT Next 3Y48.73%
EBIT Next 5YN/A
FCF growth 1Y-69.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.68%
OCF growth 3YN/A
OCF growth 5YN/A
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to PTGX.
What is the valuation status for PTGX stock?
ChartMill assigns a valuation rating of 4 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Fairly Valued.
How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 2 / 10.
What is the earnings growth outlook for PROTAGONIST THERAPEUTICS INC?
The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to grow by 192.01% in the next year.